vs
FTI CONSULTING, INC（FCN）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是FTI CONSULTING, INC的1.4倍（$1.4B vs $990.7M），瑞思迈净利率更高（27.6% vs 5.5%，领先22.1%），瑞思迈同比增速更快（11.0% vs 10.7%），FTI CONSULTING, INC自由现金流更多（$351.4M vs $311.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs 3.3%）
FTI咨询成立于1982年，总部位于美国华盛顿特区，是全球顶尖的金融咨询服务商之一。公司核心业务涵盖企业融资与重组、经济咨询、法务与诉讼咨询、战略传播、科技及战略咨询等领域，在31个国家拥有逾7700名员工。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
FCN vs RMD — 直观对比
营收规模更大
RMD
是对方的1.4倍
$990.7M
营收增速更快
RMD
高出0.3%
10.7%
净利率更高
RMD
高出22.1%
5.5%
自由现金流更多
FCN
多$40.2M
$311.2M
两年增速更快
RMD
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $990.7M | $1.4B |
| 净利润 | $54.5M | $392.6M |
| 毛利率 | 31.1% | 61.8% |
| 营业利润率 | 9.4% | 34.6% |
| 净利率 | 5.5% | 27.6% |
| 营收同比 | 10.7% | 11.0% |
| 净利润同比 | 9.7% | 13.9% |
| 每股收益（稀释后） | $1.77 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCNRMD
| Q4 25 | $990.7M | $1.4B | ||
| Q3 25 | $956.2M | $1.3B | ||
| Q2 25 | $943.7M | $1.3B | ||
| Q1 25 | $898.3M | $1.3B | ||
| Q4 24 | $894.9M | $1.3B | ||
| Q3 24 | $926.0M | $1.2B | ||
| Q2 24 | $949.2M | $1.2B | ||
| Q1 24 | $928.6M | $1.2B |
净利润FCNRMD
| Q4 25 | $54.5M | $392.6M | ||
| Q3 25 | $82.8M | $348.5M | ||
| Q2 25 | $71.7M | $379.7M | ||
| Q1 25 | $61.8M | $365.0M | ||
| Q4 24 | $49.7M | $344.6M | ||
| Q3 24 | $66.5M | $311.4M | ||
| Q2 24 | $83.9M | $292.2M | ||
| Q1 24 | $80.0M | $300.5M |
毛利率FCNRMD
| Q4 25 | 31.1% | 61.8% | ||
| Q3 25 | 33.3% | 61.5% | ||
| Q2 25 | 32.1% | 60.8% | ||
| Q1 25 | 32.2% | 59.3% | ||
| Q4 24 | 30.2% | 58.6% | ||
| Q3 24 | 32.2% | 58.6% | ||
| Q2 24 | 32.8% | 58.5% | ||
| Q1 24 | 32.6% | 57.9% |
营业利润率FCNRMD
| Q4 25 | 9.4% | 34.6% | ||
| Q3 25 | 12.3% | 33.4% | ||
| Q2 25 | 10.5% | 33.7% | ||
| Q1 25 | 8.8% | 33.0% | ||
| Q4 24 | 5.9% | 32.5% | ||
| Q3 24 | 9.8% | 31.6% | ||
| Q2 24 | 11.0% | 31.2% | ||
| Q1 24 | 10.7% | 31.3% |
净利率FCNRMD
| Q4 25 | 5.5% | 27.6% | ||
| Q3 25 | 8.7% | 26.1% | ||
| Q2 25 | 7.6% | 28.2% | ||
| Q1 25 | 6.9% | 28.3% | ||
| Q4 24 | 5.6% | 26.9% | ||
| Q3 24 | 7.2% | 25.4% | ||
| Q2 24 | 8.8% | 23.9% | ||
| Q1 24 | 8.6% | 25.1% |
每股收益（稀释后）FCNRMD
| Q4 25 | $1.77 | $2.68 | ||
| Q3 25 | $2.60 | $2.37 | ||
| Q2 25 | $2.13 | $2.58 | ||
| Q1 25 | $1.74 | $2.48 | ||
| Q4 24 | $1.39 | $2.34 | ||
| Q3 24 | $1.85 | $2.11 | ||
| Q2 24 | $2.34 | $1.97 | ||
| Q1 24 | $2.23 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $265.1M | $1.4B |
| 总债务越低越好 | — | $403.9M |
| 股东权益账面价值 | $1.7B | $6.3B |
| 总资产 | $3.5B | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资FCNRMD
| Q4 25 | $265.1M | $1.4B | ||
| Q3 25 | $146.0M | $1.4B | ||
| Q2 25 | $152.8M | $1.2B | ||
| Q1 25 | $151.1M | $932.7M | ||
| Q4 24 | $660.5M | $521.9M | ||
| Q3 24 | $386.3M | $426.4M | ||
| Q2 24 | $226.4M | $238.4M | ||
| Q1 24 | $244.0M | $237.9M |
总债务FCNRMD
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | $0 | $662.9M | ||
| Q3 24 | — | $667.6M | ||
| Q2 24 | $60.0M | $697.3M | ||
| Q1 24 | $205.0M | $997.0M |
股东权益FCNRMD
| Q4 25 | $1.7B | $6.3B | ||
| Q3 25 | $1.7B | $6.1B | ||
| Q2 25 | $1.9B | $6.0B | ||
| Q1 25 | $2.1B | $5.5B | ||
| Q4 24 | $2.3B | $5.3B | ||
| Q3 24 | $2.3B | $5.2B | ||
| Q2 24 | $2.1B | $4.9B | ||
| Q1 24 | $2.1B | $4.6B |
总资产FCNRMD
| Q4 25 | $3.5B | $8.5B | ||
| Q3 25 | $3.5B | $8.3B | ||
| Q2 25 | $3.5B | $8.2B | ||
| Q1 25 | $3.3B | $7.6B | ||
| Q4 24 | $3.6B | $7.1B | ||
| Q3 24 | $3.5B | $7.2B | ||
| Q2 24 | $3.4B | $6.9B | ||
| Q1 24 | $3.3B | $6.8B |
负债/权益比FCNRMD
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | 0.00× | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | 0.03× | 0.14× | ||
| Q1 24 | 0.10× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $359.8M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $351.4M | $311.2M |
| 自由现金流率自由现金流/营收 | 35.5% | 21.9% |
| 资本支出强度资本支出/营收 | 0.8% | 2.0% |
| 现金转化率经营现金流/净利润 | 6.60× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $93.6M | $1.8B |
8季度趋势，按日历期对齐
经营现金流FCNRMD
| Q4 25 | $359.8M | $339.7M | ||
| Q3 25 | $201.9M | $457.3M | ||
| Q2 25 | $55.7M | $538.8M | ||
| Q1 25 | $-465.2M | $578.7M | ||
| Q4 24 | $315.3M | $308.6M | ||
| Q3 24 | $219.4M | $325.5M | ||
| Q2 24 | $135.2M | $440.1M | ||
| Q1 24 | $-274.8M | $402.0M |
自由现金流FCNRMD
| Q4 25 | $351.4M | $311.2M | ||
| Q3 25 | $187.0M | $414.4M | ||
| Q2 25 | $38.3M | $508.2M | ||
| Q1 25 | $-483.0M | $557.9M | ||
| Q4 24 | $301.6M | $288.0M | ||
| Q3 24 | $212.3M | $307.7M | ||
| Q2 24 | $125.2M | $415.2M | ||
| Q1 24 | $-279.5M | $380.8M |
自由现金流率FCNRMD
| Q4 25 | 35.5% | 21.9% | ||
| Q3 25 | 19.6% | 31.0% | ||
| Q2 25 | 4.1% | 37.7% | ||
| Q1 25 | -53.8% | 43.2% | ||
| Q4 24 | 33.7% | 22.5% | ||
| Q3 24 | 22.9% | 25.1% | ||
| Q2 24 | 13.2% | 33.9% | ||
| Q1 24 | -30.1% | 31.8% |
资本支出强度FCNRMD
| Q4 25 | 0.8% | 2.0% | ||
| Q3 25 | 1.6% | 3.2% | ||
| Q2 25 | 1.8% | 2.3% | ||
| Q1 25 | 2.0% | 1.6% | ||
| Q4 24 | 1.5% | 1.6% | ||
| Q3 24 | 0.8% | 1.5% | ||
| Q2 24 | 1.1% | 2.0% | ||
| Q1 24 | 0.5% | 1.8% |
现金转化率FCNRMD
| Q4 25 | 6.60× | 0.87× | ||
| Q3 25 | 2.44× | 1.31× | ||
| Q2 25 | 0.78× | 1.42× | ||
| Q1 25 | -7.52× | 1.59× | ||
| Q4 24 | 6.34× | 0.90× | ||
| Q3 24 | 3.30× | 1.05× | ||
| Q2 24 | 1.61× | 1.51× | ||
| Q1 24 | -3.44× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCN
| Corporate Finance Segment | $423.2M | 43% |
| Forensic And Litigation Consulting | $192.9M | 19% |
| Economic Consulting | $176.2M | 18% |
| Strategic Communications | $99.4M | 10% |
| Other | $99.0M | 10% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
